We have therefore set up a multicenter 5-year prospective cohort and associated biobank named ASSESS (Assessment of Systemic Signs and Evolution in Sjögren's Syndrome) in France in order to determine whether serum BAFF, beta2-microglobulin, free light chains of immunoglobulins (primary objective) or other serum or mRNA markers (secondary objectives) could predict the occurrence of systemic complications including lymphoma. This evidence concerns the gene TNFSF13B and lymphoma.